Crossmark

The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-019-5519-2

Published Online: 2019-03-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Chang-Ying

Zhu, Qian

Tou, Fang-Fang

Wen, Xiao-Ming

Kuang, Yu-Kang

Hu, Hao
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81560382)

Jiangxi Province’s Program of the Preponderant Team Building in Science and Technology Innovation (20161BCB24011)

Key Research and Development Program of Jiangxi Province (20181BBG70017)
License Information

Text and Data Mining valid from 2019-03-29
More Information

Article History

Received: 19 January 2019

Accepted: 25 March 2019

First Online: 29 March 2019

Ethics approval and consent to participate

: Approval for retrospective analysis of the patient data was obtained from the ethics committee of the Jiangxi Cancer Hospital. Because this is a retrospective study, the ethics committee of Jiangxi Cancer Hospital also waived the need for written consent; verbal consent was obtained from the patients via telephone and documented in the informed consent form if the patient agreed to participate in this study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.